BMJ, doi: 10.1136/bmj.37977.653750.EE, (Published 2 February 2004)

PAPERS

Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study

Christopher V Plowe 1, James G Kublin 1, Fraction K Dzinjalamala 2, Deborah S Kamwendo 2, Rabia A G Mukadam 2, Phillips Chimpeni 2, Malcolm E Molyneux 3, Terrie E Taylor 4

1 Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, HSF1-480, Baltimore, MD 21044, USA
2 Blantyre Malaria Project, College of Medicine, University of Malawi, Blantyre, Malawi
3 Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi
4 College of Osteopathic Medicine, Michigan State University, Lansing, MI, USA

Objective To measure the efficacy of sulfadoxine-pyrimethamine treatment of falciparum malaria in Malawi from 1998 to 2002, after a change from chloroquine to sulfadoxine-pyrimethamine as first line treatment in that country in 1993.

Design Prospective open label drug efficacy study.

Setting Health centre in large peri-urban township adjacent to Blantyre, Malawi.

Participants People presenting to a health centre with uncomplicated Plasmodium falciparum malaria.

Main outcome measures Therapeutic efficacy and parasitological resistance to standard sulfadoxine-pyrimethamine treatment at 14 days and 28 days of follow up.

Results Therapeutic efficacy remained stable, with adequate clinical response rates of 80% or higher throughout the five years of the study. Analysis of follow up to 28 days showed modest but significant trends towards diminishing clinical and parasitological efficacy over time within the study period.

Conclusion Contrary to expectations, sulfadoxine-pyrimethamine has retained good efficacy after 10 years as the first line antimalarial drug in Malawi. African countries with very low chloroquine efficacy, high sulfadoxine-pyrimethamine efficacy, and no other immediately available alternatives may benefit from interim use of sulfadoxine-pyrimethamine while awaiting implementation of combination antimalarial treatments.

(Accepted 2 December 2003)
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Articles

Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: Sulfadoxine-pyrimethamine is not working in Malawi
Nicholas White
BMJ 2004 328: 1259. [Extract] [Full Text] [PDF]

Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: Treatment failure and resistance in Malawi remain subject for debate
P Ringwald
BMJ 2004 328: 1259-1260. [Extract] [Full Text]

Efficacy of malaria treatment shows some decline
BMJ 2004 328: 0. [Full Text] [PDF]

Treating malaria in Africa
Brian Greenwood
BMJ 2004 328: 534-535. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Asih, P. B. S., Dewi, R. M., Tuti, S., Sadikin, M., Sumarto, W., Sinaga, B., van der Ven, A. J. A. M., Sauerwein, R. W., Syafruddin, D. (2009). Efficacy of Artemisinin-Based Combination Therapy for Treatment of Persons with Uncomplicated Plasmodium falciparum Malaria in West Sumba District, East Nusa Tenggara Province, Indonesia, and Genotypic Profiles of the Parasite. Am J Trop Med Hyg 80: 914-918 [Abstract] [Full text]  
  • Laufer, M. K., van Oosterhout, J. J. G., Thesing, P. C., Dzinjalamala, F. K., Hsi, T., Beraho, L., Graham, S. M., Taylor, T. E., Plowe, C. V. (2007). Malaria Treatment Efficacy among People Living with HIV: The Role of Host and Parasite Factors. Am J Trop Med Hyg 77: 627-632 [Abstract] [Full text]  
  • O. ter Kuile, F., van Eijk, A. M., Filler, S. J. (2007). Effect of Sulfadoxine-Pyrimethamine Resistance on the Efficacy of Intermittent Preventive Therapy for Malaria Control During Pregnancy: A Systematic Review. JAMA 297: 2603-2616 [Abstract] [Full text]  
  • Daily, J. P. (2006). Antimalarial drug therapy: the role of parasite biology and drug resistance.. J Clin Pharmacol 46: 1487-1497 [Abstract] [Full text]  
  • Laufer, M. K., Thesing, P. C., Eddington, N. D., Masonga, R., Dzinjalamala, F. K., Takala, S. L., Taylor, T. E., Plowe, C. V. (2006). Return of Chloroquine Antimalarial Efficacy in Malawi. NEJM 355: 1959-1966 [Abstract] [Full text]  
  • HAPUARACHCHI, H. C., DAYANATH, M. Y. D., BANDARA, K. B. A. T., ABEYSUNDARA, S., ABEYEWICKREME, W., DE SILVA, N. R., HUNT, S. Y., SIBLEY, C. H. (2006). POINT MUTATIONS IN THE DIHYDROFOLATE REDUCTASE AND DIHYDROPTEROATE SYNTHASE GENES OF PLASMODIUM FALCIPARUM AND RESISTANCE TO SULFADOXINE-PYRIMETHAMINE IN SRI LANKA. Am J Trop Med Hyg 74: 198-204 [Abstract] [Full text]  
  • PITMANG, S. L., THACHER, T. D., MADAKI, J. K. A., EGAH, D. Z., FISCHER, P. R. (2005). COMPARISON OF SULFADOXINE-PYRIMETHAMINE WITH AND WITHOUT CHLOROQUINE FOR UNCOMPLICATED MALARIA IN NIGERIA. Am J Trop Med Hyg 72: 263-266 [Abstract] [Full text]  
  • Gregson, A., Plowe, C. V. (2005). Mechanisms of Resistance of Malaria Parasites to Antifolates. Pharmacol. Rev. 57: 117-145 [Abstract] [Full text]  
  • SYAFRUDDIN, D., ASIH, P. B. S., CASEY, G. J., MAGUIRE, J., BAIRD, J. K., NAGESHA, H. S., COWMAN, A. F., REEDER, J. C. (2005). MOLECULAR EPIDEMIOLOGY OF PLASMODIUM FALCIPARUM RESISTANCE TO ANTIMALARIAL DRUGS IN INDONESIA. Am J Trop Med Hyg 72: 174-181 [Abstract] [Full text]  
  • Stepniewska, K., Taylor, W. R.J., Mayxay, M., Price, R., Smithuis, F., Guthmann, J.-P., Barnes, K., Myint, H. Y., Adjuik, M., Olliaro, P., Pukrittayakamee, S., Looareesuwan, S., Hien, T. T., Farrar, J., Nosten, F., Day, N. P.J., White, N. J. (2004). In Vivo Assessment of Drug Efficacy against Plasmodium falciparum Malaria: Duration of Follow-Up. Antimicrob. Agents Chemother. 48: 4271-4280 [Abstract] [Full text]  
  • White, N. (2004). Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: Sulfadoxine-pyrimethamine is not working in Malawi. BMJ 328: 1259-1259 [Full text]  
  • Ringwald, P (2004). Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: Treatment failure and resistance in Malawi remain subject for debate. BMJ 328: 1259-1260 [Full text]  
  • Greenwood, B. (2004). Treating malaria in Africa. BMJ 328: 534-535 [Full text]  

Rapid Responses:

Read all Rapid Responses

Treatment failure and resistance to sulfadoxine-pyrimethamine in Malawi
Pascal RINGWALD
bmj.com, 12 Mar 2004 [Full text]
Is sulfadoxine-pyrimethamine safe as a first line therapy
Zaki Hussain Khan
bmj.com, 18 Mar 2004 [Full text]
Sulfadoxine-pyrimethamine is not working in Malawi
Nicholas J White
bmj.com, 1 Apr 2004 [Full text]
Sustained clinical efficacy of Sulfadoxine-pyrimethamine in malawi after 10 years: recommendations should be interpreted with caution.
Ayokunle .T. Abegunde
bmj.com, 6 Apr 2004 [Full text]
Authors' response
Christopher V. Plowe, et al.
bmj.com, 7 Apr 2004 [Full text]
SP Failure rates similar in Blantyre, Malawi and KwaZulu Natal, South Africa
Karen I Barnes, et al.
bmj.com, 15 Apr 2004 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ